{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-112338","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2026-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.707953+00:00","generated_at":"2026-05-15T09:59:51.492512+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"XOMA Royalty reports 2025 net income $31.7M vs loss $13.8M; royalties up 68% YoY","bullets":["Full-year cash receipts $50.5M ($33.6M royalties, +68% YoY; $16.9M milestones); Q4 net income $6.1M vs loss $4.0M YoY.","Repurchased 648,048 shares for $16.0M; completed seven acquisitions adding 22 assets to portfolio.","Pipeline catalysts: volixibat Phase 2b data in PSC in Q2 2026; ersodetug Phase 3 data in tumor HI 2H 2026.","Seralutinib Phase 3 PAH missed primary endpoint; path forward discussions with FDA ongoing.","Litigation vs Janssen over TREMFYA IP continues; G&A includes $1.1M legal costs in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-112338","json":"https://secwatch.observer/filing/0001193125-26-112338.json","markdown":"https://secwatch.observer/filing/0001193125-26-112338.md","text":"https://secwatch.observer/filing/0001193125-26-112338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312526112338/0001193125-26-112338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312526112338/d34671d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:59:51.492512+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}